first approved treatment using rnai – alnylam pharmaceuticals’ and bio chair john maraganore
Published 6 years ago • 2.1K plays • Length 3:26Download video MP4
Download video MP3
Similar videos
-
3:34
rnai therapeutics - how this new class of medicines works
-
2:56
rnai therapeutics - how this new class of medicines works
-
2:32
what is rnai and how do rnai-based medicines work?
-
59:30
founder stories: john maraganore, ceo of alnylam pioneering rnai therapeutics
-
1:14
john maraganore speaks out on his role as bio chair
-
36:13
ep. 60 - jmm john maraganore: a higher bar for investment is a credit to biotech
-
4:51
john maraganore, ph.d., chief executive officer, alnylam pharmaceuticals, inc. at bio 2017
-
13:00
gene silencing methods: crispr vs. talens vs. rnai
-
27:33
founder stories: john maraganore, ceo of alnylam pharmaceuticals
-
1:05
alnylam pharma and the science of rnai
-
8:55
(arwr) arrowhead pharmaceuticals stock analysis, why the technology is inferior
-
2:19
get to know alnylam - the leader in rnai therapeutics
-
1:01
alnylam targets “undruggable” diseases
-
2:04
the dreamers - developing a new class of medicines
-
2:20
the pioneers - developing a new class of medicines
-
2:43
from possibility to patients: the scientific odyssey - the rnai boom
-
2:20
the futurists - developing a new class of medicines
-
2:17
the heroes - developing a new class of medicines
-
0:43
alnylam and amicus drugs win approval from fda
-
2:38
trailer - developing a new class of medicines
-
2:01
rnai explained